Abstract
Activation of beta adrenergic receptors in the isolated rabbit heart by catecholamines stimulates prostacyclin (PGI2) synthesis, which is inhibited by adenosine 3′5′-cyclic monophosphate (cAMP). The purpose of this study was to determine if activation of beta adrenergic receptors in cultured coronary endothelial cells (CEC) of rabbit heart with isoproterenol (ISOP) stimulates PGI2 synthesis and if cAMP inhibits the synthesis of this prostanoid and to investigate the underlying mechanism. Incubation of CEC with ISOP increased production of cAMP and PGI2, measured as immunoreactive cAMP and 6-keto-prostaglandin F1α, (6-keto-PGF1α), respectively. Forskolin, an activator of adenylyl cyclase, increased cAMP accumulation and inhibited ISOP-stimulated 6-keto-PGF1α synthesis. 8-(4-chlorophenylthio) cAMP also inhibited ISOP-induced 6-keto-PGF1α production. However, miconazole, an inhibitor of adenylyl cyclase, reduced cAMP accumulation and enhanced ISOP-stimulated 6-keto-PGF1α synthesis in CEC. ISOP-induced 6-keto-PGF1α synthesis was attenuated by C2-ceramide, an inhibitor of phospholipase D (PLD) by propranolol, a beta-AR antagonist that also inhibits phosphatidate phosphohydrolase and by the diacylglycerol lipase inhibitor 1,6-bis-(cyclohexyloximinocarbonylamino)-hexane (RHC 80267). Acetylcholine (ACh) induced 6-keto-PGF1α synthesis was also inhibited by these agents. Both ISOP and ACh increased PLD activity, which was inhibited by C2-ceramide but not by RHC 80267 or propranolol. ACh but not ISOP increased phospholipase A2 activity in CEC. ISOP- but not ACh-induced increase in PLD activity was attenuated by forskolin and 8-(4-chlorophenyl-thio)-adenosine 3′-5′-cyclic monophosphate and augmented by miconazole. These data suggest thatbeta adrenergic receptors activation promotes PGI2 synthesis in the CEC by selective activation of PLD and that cAMP decreases PGI2 synthesis by decreasing PLD activity. Moreover, beta adrenergic receptors activated PLD appears to be distinct from that stimulated by ACh.
Footnotes
-
Send reprint requests to: Dr. Kafait U. Malik, Professor Pharmacology College of Medicine, The University of Tennessee, Memphis 874 Union Avenue, Memphis, TN 38163.
-
↵1 This study was supported by USPHS-NIH Grant 19134-22 from the National Heart, Lung and Blood Institute. This work was presented in part at the Annual FASEB Meeting, April 1994, Anaheim, CA.
-
↵2 Current address: Dr. Ying Ruan, Department of Pharmacology, University of Nebraska Medical Center, 600 South 42nd Street, Omaha, NE 68198-6260.
-
↵3 Current address: Dr. Hong Kan, Department of Medicine, Section of Cardiology, West Virginia University Health Sciences Center, P.O. Box 9157, Morgantown, WV 26506.
- Abbreviations:
- AA
- arachidonic acid
- ACh
- acetylcholine
- AR
- adrenergic receptor
- cAMP
- adenosine 3′5′-cyclic monophosphate
- CEC
- coronary endothelial cells
- cpt-cAMP
- 8-(4-chlorophenyl-thio)-cAMP
- DAG
- diacylglycerol
- D-609
- tricyclodecan-9-yl xanthogenate · K
- HELSS
- e-6(bromomethylene)tetrahydro-3-(1-naphthalenyl)-2H-pyran-2one
- IBMX
- 3-isobutyl-1-methyl-xanthine
- ISOP
- isoproterenol
- PG
- prostaglandins
- PGI2
- prostacyclin
- PLA2
- phospholipase A2
- PLD
- phospholipase D
- PPH
- phosphatidate phosphohydrolase
- RHC 80267
- 1,6-bis-(cyclohexyloximinocarbonylamino)-hexane
- KHB
- Krebs-Henseleit buffer
- PEt
- phosphatidylethanol
- Received November 11, 1996.
- Accepted February 18, 1997.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|